• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Mukesh G. Harisinghani, MD


  • Hedgire SS, Oei TN, McDermott S, Cao K, Patel M Z, Harisinghani MG.Multiparametric magnetic resonance imaging of prostate cancer.Indian J Radiol Imaging. 2012 Jul;22(3):160-9.
  • Preston MA, Harisinghani MG, Mucci L, Witiuk K, Breau RH.Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer.BJU Int. 2013 Mar;111(3):514-7.
  • Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C.Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields.Radiother Oncol. 2013 Jan;106(1):64-8.
  • Hedgire SS, Elmi A, Nadkarni ND, Cao K, McDermott S, Harisinghani MG.Preoperative evaluation of perinephric fat invasion in patients with renal cell carcinoma: correlation with pathological findings.Clin Imaging.;37(1):91-6.
  • Jhaveri KS, Harisinghani MG.Guest editors.Radiol Clin North Am. 2012 Nov;50(6):xi.
  • Hedgire SS, Pargaonkar VK, Elmi A, Harisinghani AM, Harisinghani MG.Pelvic nodal imaging.Radiol Clin North Am. 2012 Nov;50(6):1111-25.
  • Hartman RI, Chang CY, Wo JY, Eisenberg JD, Hong TS, Harisinghani MG, Gazelle GS, Pandharipande PV.Optimizing Adjuvant Treatment Decisions for Stage T2 Rectal Cancer Based on Mesorectal Node Size: A Decision Analysis.Acad Radiol. 2012 Sep 1.
  • Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.N Engl J Med. 2011 Feb 17;364(7):667-75.
  • Saokar A, Gee MS, Islam T, Mueller PR, Harisinghani MG.Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10.Clin Imaging.;34(6):448-52.
  • Islam T, Harisinghani MG.Prostate cancer imaging: what the next decade holds.Expert Rev Med Devices. 2010 Sep;7(5):577-9.
  • Saokar A, Islam T, Jantsch M, Saksena MA, Hahn PF, Harisinghani MG.Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging.Clin Imaging.;34(5):361-6.
  • Pandharipande PV, Gervais DA, Hartman RI, Harisinghani MG, Feldman AS, Mueller PR, Gazelle GS.Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.Radiology. 2010 Sep;256(3):836-46.
  • Macdonald SM, Harisinghani MG, Katkar A, Napolitano B, Wolfgang J, Taghian AG.Nanoparticle-Enhanced MRI to Evaluate Radiation Delivery to the Regional Lymphatics for Patients With Breast Cancer.Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1098-104.
  • Uppot RN, Harisinghani MG, Gervais DA.Imaging-guided percutaneous renal biopsy: rationale and approach.AJR Am J Roentgenol. 2010 Jun;194(6):1443-9. Review.
  • Eisner BH, Kurtz MP, Harisinghani MG.Evolving role of magnetic resonance imaging in renal cancer imaging.J Endourol. 2010 May;24(5):707-11.
  • Iyer VR, Hahn PF, Blaszkowsky LS, Thayer SP, Halpern EF, Harisinghani MG.Added value of selected images embedded into radiology reports to referring clinicians.J Am Coll Radiol. 2010 Mar;7(3):205-10.
  • Ventura E, Islam T, Gee MS, Mahmood U, Braschi M, Harisinghani MG.Detection of nodal metastatic disease in patients with non-small cell lung cancer: comparison of positron emission tomography (PET), contrast-enhanced computed tomography (CT), and combined PET-CT.Clin Imaging.;34(1):20-8.
  • Kaufman DS, McDougal WS, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.N Engl J Med. 2009 Sep 24;361(13):1292-9.
  • Baier ND, Hahn PF, Gervais DA, Samir A, Halpern EF, Mueller PR, Harisinghani MG.Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients.AJR Am J Roentgenol. 2009 Oct;193(4):1175-9.
  • Roedl JB,Blake MA,Holalkere NS,Mueller PR,Colen RR,Harisinghani MG.Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters.Abdom Imaging.;34(5):610-7.
  • Pandharipande PV, Mora JT, Uppot RN, Goehler A, Braschi M, Halpern EF, Gazelle GS, Harisinghani MG.Lymphotropic nanoparticle-enhanced MRI for independent prediction of lymph node malignancy: a logistic regression model.AJR Am J Roentgenol. 2009 Sep;193(3):W230-7.
  • Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M.Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.Clin Imaging.;33(4):301-5.
  • Islam T,Harisinghani MG.Overview of nanoparticle use in cancer imaging.Cancer Biomark. 2009;5(2):61-7. Review.
  • Harisinghani MG.Nanoparticle enhanced imaging.Cancer Biomark. 2009;5(2):59.
  • Gee MS,Harisinghani MG,Tabatabaei S.Molecular imaging in urologic surgery.Urol Clin North Am. 2009 May;36(2):125-32. Review.
  • Pandharipande PV,Harisinghani MG,Ozanne EM,Specht MC,Hur C,Lee JM,Gazelle GS.Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis.AJR Am J Roentgenol. 2008 Nov;191(5):1308-19.
  • Roedl JB,Harisinghani MG,Colen RR,Fischman AJ,Blake MA,Mathisen DJ,Mueller PR.Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.Ann Thorac Surg. 2008 Oct;86(4):1131-8.
  • Li CS,Harisinghani MG,Lin WC,Braschi M,Hahn PF,Mueller PR.Enhancement characteristics of ultrasmall superparamagnetic iron oxide particle within the prostate gland in patients with primary prostate cancer.J Comput Assist Tomogr. 2008 Jul-Aug;32(4):523-8.
  • Michaelson MD,Iliopoulos O,McDermott DF,McGovern FJ,Harisinghani MG,Oliva E.Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.N Engl J Med. 2008 May 29;358(22):2389-96.
  • Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG.Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer.Urology. 2008 Apr;71(4):708-12.
  • Feldman AS, McDougal WS, Harisinghani MG.The potential of nanoparticle-enhanced imaging.Urol Oncol. 2008 Jan-Feb;26(1):65-73. Review.
  • Harisinghani M, Ross RW, Guimaraes AR, Weissleder R.Utility of a new bolus-injectable nanoparticle for clinical cancer staging.Neoplasia. 2007 Dec;9(12):1160-5.
  • Singh AK, Gonzalez-Torrez P, Kaewlai R, Tabatabaei S, Harisinghani MG.Imaging of penile neoplasm.Semin Ultrasound CT MR. 2007 Aug;28(4):287-96. Review.
  • Ross R, Harisinghani M.Prostate cancer imaging--what the urologic oncologist needs to know.Radiol Clin North Am. 2006 Sep;44(5):711-22, viii. Review.
  • Ross R, Harisinghani M.New clinical imaging modalities in prostate cancer.Hematol Oncol Clin North Am. 2006 Aug;20(4):811-30. Review.
  • Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R.Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy.Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1262-9.
  • Kim JY, Harisinghani MG.MR imaging staging of pelvic lymph nodes.Magn Reson Imaging Clin N Am. 2004 Aug;12(3):581-6.
  • Harisinghani MG, Dixon WT, Saksena MA, Brachtel E, Blezek DJ, Dhawale PJ, Torabi M, Hahn PF.MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10.Radiographics. 2004 May-Jun;24(3):867-78.
  • Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R.Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.N Engl J Med. 2003 Jun 19;348(25):2491-9.